🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  2. The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in treatment of uncomplicated lower urinary tract infections.

    Sciencepharma Sp. z o.o

    Not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial

  3. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of schizophrenia in adult patients.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  4. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  5. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  6. Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

    Hoffmann-La Roche

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

  7. To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  8. To evaluate the pharmacokinetics and safety of nolasiban

    Novo Nordisk A/S

    not applicable (submitted trial is a pharmacokinetic study in healthy subjects)

    phase 1 other active

    1 trial

  9. Tofacitinib tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Amyotrophic Lateral Sclerosis

    phase 1 small molecule active

    1 trial

  10. Topiramate 2 x 25 mg tablet

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  11. Topiramate Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    1 trial

  12. Trandolapril 4 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  13. Trastuzumab

    Hoffmann-La Roche

    Early Breast Cancer

    phase 1 small molecule completed

    1 trial

  14. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  15. Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

    Daiichi Sankyo

    Locally advanced/metastatic breast or non-small cell lung cancer

    phase 1 other active

    1 trial

  16. Treatment as usual (TAU)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 1 other completed

    1 trial

  17. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  18. Treatment sequence AB

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  19. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors

    Genmab A/S

    Advanced Malignant Solid Tumors

    phase 1 other active

    1 trial

  20. Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

  21. Triamcinolone Acetonide Extended-Release Injectable Suspension

    Pacira Ireland Limited

    Osteoarthritis, Knee

    phase 1 small molecule completed

    1 trial

  22. Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  23. Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

    Merck Sharp and Dohme

    Metastatic or Locally Advanced Unresectable Solid Tumors

    phase 1 other active

    1 trial

  24. UB-421 SC(dB4C7C22-6 mAb)

    United Therapeutics Europe Ltd

    HIV-1 Infection

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources